Abstract | OBJECTIVE: METHODS: RESULTS: Ten of 24 patients (42%) had major response to the gemcitabine and paclitaxel regimen, including 2 patients (8%) who had complete response. Median survival time and median progression-free survival were 12.4 and 6.1 months, respectively. Good performance status and major response to first-line methotrexate, vinblastine, doxorubicin and cisplatin treatment were significant predictors of overall survival and progression-free survival. Grade 3 or 4 neutropenia occurred in 16 patients (67%), but there were no severe infections. There were no treatment-related deaths. CONCLUSIONS:
|
Authors | Masaomi Ikeda, Kazumasa Matsumoto, Ken-Ichi Tabata, Satoru Minamida, Tetsuo Fujita, Takefumi Satoh, Masatsugu Iwamura, Shiro Baba |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 41
Issue 10
Pg. 1214-20
(Oct 2011)
ISSN: 1465-3621 [Electronic] England |
PMID | 21903707
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Deoxycytidine
- Vinblastine
- Doxorubicin
- Paclitaxel
- Cisplatin
- Methotrexate
- Gemcitabine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Transitional Cell
(drug therapy)
- Cisplatin
(administration & dosage)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Male
- Methotrexate
(administration & dosage)
- Middle Aged
- Paclitaxel
(administration & dosage, adverse effects)
- Survival Analysis
- Urinary Bladder Neoplasms
(drug therapy)
- Urologic Neoplasms
(drug therapy)
- Vinblastine
(administration & dosage)
- Gemcitabine
|